CD44 as a cancer stem cell marker and its prognostic value in patients with ovarian carcinoma
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11140%2F18%3A10367737" target="_blank" >RIV/00216208:11140/18:10367737 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00669806:_____/18:10367737
Výsledek na webu
<a href="http://dx.doi.org/10.1080/01443615.2017.1336753" target="_blank" >http://dx.doi.org/10.1080/01443615.2017.1336753</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1080/01443615.2017.1336753" target="_blank" >10.1080/01443615.2017.1336753</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
CD44 as a cancer stem cell marker and its prognostic value in patients with ovarian carcinoma
Popis výsledku v původním jazyce
The aim of our study was to clarify whether the CD44 adhesion molecule as a cancer stem cell marker could also serve as a prognostic factor in patients with epithelial ovarian cancer (EOC). A retrospective study was performed on 87 patients with histologically verified EOC. Specimens of both primary tumour and implantation metastases were tested from 48 of them. CD44 expression was detected by immunohistochemistry. We looked for the cut-off levels of CD44 expression using the Cox regression model. We confirmed statistically significant prognostic factors for overall survival (OS) and disease-free interval (DFI) to be: stage of the disease, postoperative residual tumour and papillary serous histological type. We demonstrated a statistically significant correlation between low CD44 expression and serous papillary carcinoma histotype, tumour recurrence and chemoresistance at a value below 2%. CD44 was neither a prognostic factor of OS nor of DFI.
Název v anglickém jazyce
CD44 as a cancer stem cell marker and its prognostic value in patients with ovarian carcinoma
Popis výsledku anglicky
The aim of our study was to clarify whether the CD44 adhesion molecule as a cancer stem cell marker could also serve as a prognostic factor in patients with epithelial ovarian cancer (EOC). A retrospective study was performed on 87 patients with histologically verified EOC. Specimens of both primary tumour and implantation metastases were tested from 48 of them. CD44 expression was detected by immunohistochemistry. We looked for the cut-off levels of CD44 expression using the Cox regression model. We confirmed statistically significant prognostic factors for overall survival (OS) and disease-free interval (DFI) to be: stage of the disease, postoperative residual tumour and papillary serous histological type. We demonstrated a statistically significant correlation between low CD44 expression and serous papillary carcinoma histotype, tumour recurrence and chemoresistance at a value below 2%. CD44 was neither a prognostic factor of OS nor of DFI.
Klasifikace
Druh
J<sub>imp</sub> - Článek v periodiku v databázi Web of Science
CEP obor
—
OECD FORD obor
30214 - Obstetrics and gynaecology
Návaznosti výsledku
Projekt
—
Návaznosti
S - Specificky vyzkum na vysokych skolach
Ostatní
Rok uplatnění
2018
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Journal of Obstetrics and Gynaecology
ISSN
0144-3615
e-ISSN
—
Svazek periodika
38
Číslo periodika v rámci svazku
1
Stát vydavatele periodika
GB - Spojené království Velké Británie a Severního Irska
Počet stran výsledku
5
Strana od-do
110-114
Kód UT WoS článku
000423409800021
EID výsledku v databázi Scopus
2-s2.0-85027836842